{"id":"vonoprazan-amoxicillin-clarithromycin-14-days","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal discomfort"},{"rate":"5-8","effect":"Taste disturbance"},{"rate":"3-5","effect":"Headache"},{"rate":"1-3","effect":"Allergic reaction (amoxicillin)"}]},"_chembl":{"chemblId":"CHEMBL2105950","moleculeType":"Small molecule","molecularWeight":"387.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits the H+/K+-ATPase pump to reduce gastric acid secretion, creating an environment where amoxicillin and clarithromycin can effectively penetrate and kill H. pylori. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis, while clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis. The combination achieves high eradication rates through synergistic bactericidal and bacteriostatic mechanisms.","oneSentence":"This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid with vonoprazan while amoxicillin and clarithromycin attack the bacteria directly.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:34.223Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori eradication in peptic ulcer disease"},{"name":"H. pylori-associated chronic gastritis"}]},"trialDetails":[{"nctId":"NCT07179159","phase":"NA","title":"Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial","status":"RECRUITING","sponsor":"Yanqing Li","startDate":"2025-09-09","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":372},{"nctId":"NCT07224035","phase":"PHASE4","title":"Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2022-10-15","conditions":"H Pylori Infection, H Pylori Gastritis, Gastric Cancer","enrollment":500},{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":"Helicobacter Pylori Infection","enrollment":337},{"nctId":"NCT07068607","phase":"PHASE4","title":"Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2025-04-01","conditions":"Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer","enrollment":400},{"nctId":"NCT06514274","phase":"PHASE4","title":"Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-09-20","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":558},{"nctId":"NCT07040839","phase":"PHASE4","title":"Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Rehman Medical Institute - RMI","startDate":"2025-07","conditions":"H Pylori","enrollment":128},{"nctId":"NCT06576882","phase":"PHASE3","title":"7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-06-30","conditions":"Helicobacter Pylori Infection, Gastritis, Vonoprazan","enrollment":326},{"nctId":"NCT05957432","phase":"PHASE2","title":"Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2023-08-15","conditions":"Helicobacter Pylori Infection","enrollment":90},{"nctId":"NCT06162949","phase":"PHASE3","title":"Vonoprazan for Helicobacter Pylori Eradication in Adolescents","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-01-01","conditions":"Treatment Effectiveness","enrollment":242},{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT06414707","phase":"PHASE3","title":"Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-10-12","conditions":"Helicobacter Pylori Infection","enrollment":320},{"nctId":"NCT06101420","phase":"PHASE3","title":"Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":"Helicobacter Pylori Eradication","enrollment":232},{"nctId":"NCT06037122","phase":"","title":"Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09","conditions":"Helicobacter Pylori Infection","enrollment":558},{"nctId":"NCT04753437","phase":"PHASE1","title":"A Study of Vonoprazan in Adults With Helicobacter Pylori","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-04-06","conditions":"Helicobacter Pylori","enrollment":44},{"nctId":"NCT06004401","phase":"NA","title":"The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2023-08-20","conditions":"The Eradication Rate of Helicobacter Pylori","enrollment":400},{"nctId":"NCT05049902","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-09-21","conditions":"Helicobacter Pylori Infection","enrollment":1300},{"nctId":"NCT05014334","phase":"PHASE4","title":"Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2021-12-01","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":300},{"nctId":"NCT05345210","phase":"PHASE4","title":"Vonoprazan Hp Dual or Triple Eradication Regimes","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-04-25","conditions":"Helicobacter Pylori","enrollment":500},{"nctId":"NCT04167670","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2019-12-10","conditions":"Helicobacter Pylori Infection","enrollment":1046},{"nctId":"NCT05196945","phase":"PHASE4","title":"Vonoprazan Fumarate in Combination With Amoxicillin for the First-line Eradication of Helicobacter Pylori -- a Multicenter, Randomized, Parallel Controlled Study","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2022-03-31","conditions":"Helicobacter Pylori Eradication Rate","enrollment":316},{"nctId":"NCT05191888","phase":"PHASE4","title":"14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2021-08-06","conditions":"Helicobacter Pylori Eradication","enrollment":906},{"nctId":"NCT05126121","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Xiuli Zuo","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05133193","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT04991584","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-08-04","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT04901117","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-06","conditions":"Helicobacter Pylori Infection","enrollment":1300},{"nctId":"NCT03908619","phase":"PHASE4","title":"A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis","status":"UNKNOWN","sponsor":"Changi General Hospital","startDate":"2019-04-16","conditions":"Helicobacter Pylori Infection","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vonoprazan+amoxicillin+clarithromycin 14 days","genericName":"Vonoprazan+amoxicillin+clarithromycin 14 days","companyName":"Xijing Hospital of Digestive Diseases","companyId":"xijing-hospital-of-digestive-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid with vonoprazan while amoxicillin and clarithromycin attack the bacteria directly. Used for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated chronic gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}